Skip to content

Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions

Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions: a Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03525912
Enrollment
101
Registered
2018-05-16
Start date
2017-07-01
Completion date
2018-11-14
Last updated
2019-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ketamine Adverse Reaction, Pain, Postoperative

Brief summary

Evaluation of neuropsychiatric and cardiovascular side effects of low dose ketamine analgesic infusion for postoperative pain

Detailed description

Postoperative pain is a world wide problem related with surgery. Multimodal analgesia may include ketamine, aimed to decrease opioid adverse effects in postoperative analgesia for major surgery, and risk of chronic postsurgical pain. Ketamine has shown efficacy as adjuvant in multimodal analgesia, however, neuropsychiatric and cardiovascular effects of ketamine at low doses in continue postoperative infusion are less known. This type of adverse effects may compromise appropriated recovery. Objective to determine frequency of delirium, agitation, sedation, hallucinations, bad dreams and cardiovascular changes associated with ketamine analgesic infusion treatment for postoperative pain.

Interventions

DRUGKetamine

continuous infusion of low dose ketamine for postoperative pain

Sponsors

Universidad de Antioquia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

single group assignment interventional

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- patient scheduled for abdominal, thoracic or orthopedic surgery

Exclusion criteria

cognitive disfunction psychiatric illness cardiovascular disease

Design outcomes

Primary

MeasureTime frameDescription
Delirium2 daysPresence or absence of delirium at 24 and 48 hours postoperatively over the past 2 days of exposure to ketamine infusion, using the Confusion Assessment Method (CAM), a clinical based assessment tool for identifying delirium. Consist of 4 criteria ( timing of symptoms, attention, thinking, consciousness). Considered to be positive for delirium if both features 1 and 2 are present, with at least one of features 3 or 4.

Secondary

MeasureTime frameDescription
Agitation24 and 48 hours postoperativelyRichmond Agitation- Sedation Scale (RASS) score is a 10 point scale with discrete criteria, with four levels of agitation (+1 to +4), one level for calm and alert state (0), and 5 levels of sedation (-1 to -5)
Sedation24 and 48 hours postoperativelyClinician based Richmond Agitation- Sedation Scale (RASS) at 24 and 48 hours. RASS is a 10 point scale with discrete criteria, with four levels of agitation (+1 to +4), one level for calm and alert state (0), and 5 levels of sedation (-1 to -5)

Other

MeasureTime frameDescription
Hallucinations24 and 48 hours postoperativelyPresence or absence of hallucinations
Tachycardia0, 24 and 48 hours postoperativelya heart rate of more than 100 beats per minute (BPM)
Bad Dreams24 and 48 hours postoperativelyPresence or absence of bad dreams
Hypertension0, 24 and 48 hours postoperativelyHypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026